// App-Quantinova.ai

3078 : Phase II open-label, multi-centre study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC.

Researchers

Presenter

  • James Lorens

Principal Investigators

  • Carlos Eduardo Arce-Lara

  • Edurne Arriola

  • Paal Brunsvig

  • Enric Carcereny Costa

  • Manuel Domine

  • Konstantin H. Dragnev

  • Enriqueta Felip

  • Rosario Garcia Campelo

  • Matthew Krebs

  • Santiago Ponce Aix

  • James F. Spicer

  • Jose Manuel Trigo Perez

  • Nuria Vinolas

  • Robert J Holt

  • Anthony Brown

  • Michael Jon Chisamore

Medical Centers

  • BergenBio AS, Bergen, Norway

  • The Medical College of Wisconsin, Milwaukee, WI

  • Hospital Del Mar, Barcelona, Spain

  • Radiumhospitalet (The Norwegian Radium Hospital), Oslo, Norway

  • Medical Oncology Department. Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain

  • Oncology Department and Translational Oncology Division, Fundacion Jimenez Diaz Hospital, Madrid, Spain

  • Dartmouth Hitchcock Medical Center, Lebanon, NH

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Hospital Teresa Herrera/CHUAC, A Coruna, Spain

  • The Christie NHS Foundation Trust and The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom

  • Hospital Doce de Octubre, Madrid, Spain

  • Kings College London, London, United Kingdom

  • Hospital Virgen de la Victoria, Malaga, Spain

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Merck & Co. Inc., Rahway, NJ

Locations

  • United States

  • Spain

  • United Kingdom

  • Norway

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Anaplastic lymphoma Kinase

  • AXL receptor tyrosine kinase

  • Programmed death-ligand 1

  • Epidermal growth factor receptor

Drug/Treatment

  • Pembrolizumab

  • R428

  • BGB-324

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Multicenteric

Phase

  • II

Study Id's

  • NCT03184571

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved